On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Bristow Group, Inc. (NYSE:BRS), Prothena Corporation plc (PRTA), Kansas City Southern (NYSE:KSU), Nxt-ID, Inc. (NASDAQ:NXTD)
Bristow Group, Inc. (NYSE:BRS), with shares declined -8.01%, closed at $52.25, hitting new 52-week low of $51.29.
Prothena Corporation plc (PRTA), with shares dropped -2.41%, settled at $37.73.
Kansas City Southern (NYSE:KSU), with shares dipped -7.96%, and closed at $106.48.
Nxt-ID, Inc. (NASDAQ:NXTD), plummeted -7.75%, and closed at $3.57.
Latest NEWS regarding these Stocks are depicted underneath:
Bristow Group, Inc. (NYSE:BRS)
Bristow Group, Inc. (BRS), is attending the Scotia Howard Weil 43rd Annual Energy Conference held in New Orleans on March 22 – 26, 2015. Jonathan E. Baliff, President and Chief Executive Officer, is planned to present on Tuesday, March 24, at 9:15 a.m. Central Time (10:15 a.m. Eastern Time).
Bristow Group Inc. provides helicopter services to the offshore energy industry in Europe, West Africa, North America, Australia, and internationally. Its helicopters are used principally to transport personnel between onshore bases and offshore production platforms, drilling rigs, and other installations, in addition to to transport time-sensitive equipment to these offshore locations.
Prothena Corporation plc (PRTA)
Prothena Corporation plc (PRTA), a late-stage clinical biotechnology corporation focused on the discovery, development and commercialization of novel protein immunotherapy programs, declared positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson’s disease and other related synucleinopathies. PRX002 is the focus of a worldwide partnership between Prothena and Roche.
PRX002 was safe and well-tolerated, meeting the primary objective of the study. Further, results from this study showed that administration of PRX002 leads to mean reduction of free serum alpha-synuclein levels of up to 96%. These overall results were highly statistically noteworthy(p<0.00001). Reduction of free serum alpha-synuclein, a protein potentially involved in the onset and progression of Parkinson’s disease and the target of PRX002, was shown to be robust, rapid and dose-dependent after just a single dose.
The Phase 1 double-blind, placebo-controlled, single ascending dose study enrolled 40 healthy volunteers. All volunteers enrolled were randomized 3:1 into five escalating dose cohorts (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg or 30 mg/kg) to receive either PRX002 or placebo. No hypersensitivity reactions or drug-related serious adverse events were stated. PRX002 demonstrated favorable pharmacokinetic properties, supporting the current dosing frequency in the on-going Phase 1 multiple ascending dose study in patients with Parkinson’s disease. There were no treatment emergent adverse events (TEAEs) in greater than 10% of subjects. The only TEAEs in greater than 5% of subjects were vessel puncture site pain, headache and viral infection. All PRX002-related adverse events were mild and no dose limiting toxicities were observed.
In December 2013, Prothena and Roche reached a worldwide partnership to develop and commercialize antibodies that target alpha-synuclein, counting PRX002. To date, Prothena has received $45 million of the potential $600 million in total milestones through its partnership with Roche. Prothena has an option to co-promote PRX002 in the U.S., where the companies share all profits, in addition to development and commercialization costs, on a 30/70 basis (30% Prothena and 70% Roche). Outside the U.S., Roche will have sole responsibility for developing and commercializing PRX002 and will pay Prothena up to double-digit royalties on net sales.
Prothena Corporation plc, a clinical stage biotechnology corporation, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion.
Kansas City Southern (NYSE:KSU)
Kansas City Southern (KSU), is updating its guidance for full-year 2015. The Corporation now anticipates low single-digit proceed growth, reduced from the mid single-digit proceed growth offered in the previous full-year 2015 guidance issued in January 2015.
Revised Full-Year 2015 Guidance:
The reduced proceed guidance reflects slower year-to-date carload growth primarily from the energy sector, together with a continued deterioration in the value of the Mexican peso against the U.S. dollar and lower fuel surcharge proceeds driven by lower WTI prices, as shown in accompanying Chart A. As shown in the accompanying Chart B, the Corporation anticipates the influence of lower carload volumes to result in an approximate 2% lower proceed growth for the year as contrast to preceding guidance. The Corporation anticipates the combined influence of further foreign exchange rate deterioration and lower fuel surcharge proceeds to be an additional approximate 2% reduction in proceed growth as contrast to preceding guidance. The Corporation anticipates the influences of foreign exchange and fuel surcharges to be largely offset with lower expenses; however, the influence of lower carload volumes is predictable to reduce operating revenue. The Corporation is changing its guidance for linehaul proceed growth in the Energy commodity group from double-digit growth to single-digit growth for 2015. Linehaul proceed growth for all other commodity groups, overall carload growth and capital expenditures are all predictable to be in line with previous guidance.
Kansas City Southern, through its auxiliaries, engages in the freight rail transportation business. It operates north/south rail route between Kansas City, Missouri, and various ports along the Gulf of Mexico in Alabama, Louisiana, Mississippi, and Texas in the midwest and southeast regions of the United States.
Nxt-ID, Inc. (NASDAQ:NXTD)
SoundView Technology Group issues a new research update following the recent shipment of Nxt-ID, Inc. (NXTD), Wocket smart wallet. SoundView was one of the selected user groups to provide real- world user feedback on their experience with the Wocket in multiple scenarios and outlets.
Soundview shares their experience at CVS, Whole Foods and other retailers, making both debit and credit card payments.
Soundview analyst Kris Tuttle also says, “If the corporation meets their plans in 2015, it would push our IV estimate up to $17.42 for 2016.”
Nxt-ID, Inc., a technology corporation, provides various biometric solutions. The corporation develops Wocket, a physical electronic wallet that is intended to hold information from credit cards, identification cards, and virtually any magnetic stripe card to allow a specific owner of the card to configure a single electronic card to replicate any of the copied cards.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
